Price (delayed)
$22.43
Market cap
$2.52B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.01
Enterprise value
$2.49B
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and ...
Highlights
Viking Therapeutics's debt has decreased by 11% YoY and by 9% QoQ
VKTX's equity has surged by 153% year-on-year but it is down by 3.4% since the previous quarter
The company's quick ratio has surged by 74% YoY but it fell by 9% QoQ
The net income fell by 28% YoY and by 11% QoQ
The EPS has declined by 11% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of VKTX
MarketValuationsEarnings
Shares outstanding
112.25M
Market cap
$2.52B
Enterprise value
$2.49B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$150.92M
Net income
-$109.96M
EBIT
-$109.96M
EBITDA
-$109.62M
Free cash flow
-$87.79M
Per shareBalance sheetLiquidity
EPS
-$1.01
EPS diluted
-$1.01
Free cash flow per share
-$0.81
Book value per share
$7.9
Revenue per share
$0
TBVPS
$8.33
Total assets
$908.32M
Total liabilities
$28.04M
Debt
$1.12M
Equity
$880.28M
Working capital
$879.8M
Debt to equity
0
Current ratio
33.09
Quick ratio
32.93
Net debt/EBITDA
0.23
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-11.7%
Return on equity
-12.1%
Return on invested capital
-13.2%
Return on capital employed
-12.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VKTX stock price
How has the Viking Therapeutics stock price performed over time
Intraday
-7.39%
1 week
-12.55%
1 month
-20.15%
1 year
-69.56%
YTD
-44.26%
QTD
-7.12%
Financial performance
How have Viking Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$150.92M
Net income
-$109.96M
Gross margin
N/A
Net margin
N/A
VKTX financials
Viking Therapeutics's operating income has decreased by 50% YoY and by 13% from the previous quarter
The net income fell by 28% YoY and by 11% QoQ
Growth
What is Viking Therapeutics's growth rate over time
VKTX growth chart
Valuation
What is Viking Therapeutics stock price valuation
P/E
N/A
P/B
2.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has declined by 11% year-on-year and by 9% since the previous quarter
Price to book (P/B)
VKTX's equity has surged by 153% year-on-year but it is down by 3.4% since the previous quarter
The P/B is 56% less than the last 4 quarters average of 7.0 and 19% less than the 5-year quarterly average of 3.8
Price to sales (P/S)
Efficiency
How efficient is Viking Therapeutics business performance
The ROIC has soared by 59% year-on-year and by 8% since the previous quarter
Viking Therapeutics's ROE has soared by 56% YoY and by 4.7% from the previous quarter
VKTX's ROA has soared by 56% year-on-year and by 4.9% since the previous quarter
Dividends
What is VKTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VKTX.
Financial health
How did Viking Therapeutics financials performed over time
Assets vs liabilities
The total assets has soared by 146% YoY but it has contracted by 3.2% from the previous quarter
The company's quick ratio has surged by 74% YoY but it fell by 9% QoQ
Debt vs equity
Viking Therapeutics's debt is 100% lower than its equity
VKTX's equity has surged by 153% year-on-year but it is down by 3.4% since the previous quarter
Viking Therapeutics's debt has decreased by 11% YoY and by 9% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.